Emile Loria from San Diego, CA, age 75

view source

Location:

Greater San Diego Area

Industry:

Biotechnology

Treatment Of Diseases Modulated By A H4 Receptor Agonist
view source
US Patent:

8207188, Jun 26, 2012
Filed:

Jun 17, 2009
Appl. No.:

12/486725
Inventors:

Michalis Nicolaou - San Diego CA, US
Emile Loria - La Jolla CA, US
Gaetan Terrasse - Saint-Valier, FR
Yves Trehin - Blesle, FR
International Classification:

A01N 43/42
A61K 31/44
C07D 491/00
C07D 498/00
C07D 515/00
US Classification:

514292, 546 90
Abstract:

The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.

Treatment Of Copd, Gastro-Esophageal Reflux Disease (Gerd), Food Allergies And Other Gastrointestinal Conditions And Disorders Ameliorated By Proper Histamine Management Using A Combination Of Histidine Decarboxylase Inhibitors, Lra Drugs, Anti-H1 And/Or Anti-H2 Drugs
view source
US Patent:

8207292, Jun 26, 2012
Filed:

Feb 12, 2008
Appl. No.:

12/069775
Inventors:

Michalis Nicolaou - San Diego CA, US
Emile Loria - La Jolla CA, US
Gaetan Terrasse - Saint-Valiere, FR
Yves Trehin - Toulouse, FR
International Classification:

C07F 1/00
A61K 38/00
US Classification:

530206, 530217, 514 122
Abstract:

The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.

Skin Testing Kit For Diagnosing Atopy
view source
US Patent:

20060167375, Jul 27, 2006
Filed:

Oct 8, 2003
Appl. No.:

10/530832
Inventors:

Gaetan Terrassse - Montceau, FR
Yves Trehin - Toulouse, FR
Emile Loria - La Jolla CA, US
International Classification:

A61B 5/00
US Classification:

600556000
Abstract:

The instrument for the allergies' detection is a cutaneous kit which has a main body, with a sharp edge () around its circumference at the lower surface (). At least one cavity () or hollow space is coaxial to the body () for a multi-point needle (). The outer circumference of the body is bonded to the inner edge of a flexible ring (), in turn held by a rigid support () at its outer edge. The whole of the lower surface of the kit is shrouded by a blister. The cavity and the surrounding space () is filled with at least one allergenic substance. The instrument can contain three bodies with their needle assemblies.

Anti-Allergic Pharmaceutical Composition Containing At Least One Allergen And At Least One Antihistamine Compound
view source
US Patent:

20070003580, Jan 4, 2007
Filed:

Apr 28, 2006
Appl. No.:

11/413489
Inventors:

Emile Loria - La Jolla CA, US
Gaetan Terrasse - Saint-Valier, FR
Yves Trehin - Toulouse, FR
International Classification:

A61K 39/36
A61K 31/495
A61K 31/4172
A61K 31/473
US Classification:

424275100, 514255040, 514400000, 514290000
Abstract:

The present invention relates to an anti-allergic pharmaceutical composition containing at least two active agents chosen from: (i) one allergen, (ii) one antihistamine compound, and (iii) one inhibitor of histamine synthesis, said active agents being associated in said composition with a pharmaceutically acceptable vehicle.

Pure Isomers Of Tritoqualine
view source
US Patent:

20070238750, Oct 11, 2007
Filed:

Apr 9, 2007
Appl. No.:

11/784992
Inventors:

Michalis Nicolaou - San Diego CA, US
Emile Loria - La Jolla CA, US
Gaetan Terrasse - Saint-Valier, FR
Yves Trehin - Toulouse, FR
International Classification:

A61K 31/4743
C07D 491/02
US Classification:

514292, 546 90
Abstract:

The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. and FIG.

Pure Isomers Of Tritoqualine
view source
US Patent:

20120101120, Apr 26, 2012
Filed:

Aug 24, 2011
Appl. No.:

13/217072
Inventors:

Michalis Nicolaou - San Diego CA, US
Emile Loria - La Jolla CA, US
Gaetan Terrasse - Saint-Valier, FR
Yves Trehin - Blesle, FR
International Classification:

A61K 31/4741
A61P 27/14
A61P 17/04
A61P 37/02
A61P 11/06
A61P 1/00
A61P 29/00
C07D 491/056
A61P 17/00
US Classification:

514291, 546 90
Abstract:

The invention provides an isolated stereoisomer of tritoqualine having the structure of FIG. and FIG.

Treatment Of Copd, Gastro-Esophageal Reflux Disease (Gerd), Food Allergies And Other Gastrointestinal Conditions And Disorders Ameliorated By Proper Histamine Management Using A Combination Of Histidine Decarboxylase Inhibators, Lra Drugs, Anti-H1 And/Or Anti-H2 Drugs
view source
US Patent:

20120295933, Nov 22, 2012
Filed:

May 18, 2012
Appl. No.:

13/475554
Inventors:

Emile Loria - La Jolla CA, US
Michalis Nicolaou - San Diego CA, US
Gaetan Terrasse - Saint-Valier, FR
Yves Trehin - Toulouse, FR
International Classification:

A61K 31/4741
A61P 1/04
A61P 37/08
A61P 1/00
US Classification:

514291
Abstract:

The invention provides a method for the treatment of COPD and/or gastrointestinal disease conditions ameliorated by histamine management in a subject, comprising administering to the subject an effective amount of a histidine decarboxylase inhibitor.

Treatment Of Diseases Modulated By A H4 Receptor Agonist
view source
US Patent:

20130059878, Mar 7, 2013
Filed:

May 18, 2012
Appl. No.:

13/475751
Inventors:

Emile Loria - La Jolla CA, US
Michalis Nicolaou - San Diego CA, US
Gaetan Terrasse - Saint-Valier, FR
Yves Trehin - Toulouse, FR
International Classification:

A61K 31/4355
A61P 1/04
A61P 29/00
A61P 35/00
A61K 31/4545
A61K 31/4439
A61P 37/00
A61P 17/00
US Classification:

514291
Abstract:

The invention provides a method for the treatment of H4R modulated diseases and/or conditions comprising administering to the subject an effective amount of a H4R agonist. The invention also provides a method for treating COPD comprising administering to the subject an effective amount of a H4R agonist, a H1R antagonist and an anticholinergic drug. Further, the invention provides a pharmaceutical formulation comprising a H4R agonist, a second active agent and a pharmaceutically acceptable carrier.